Radius Health Inc (NASDAQ:RDUS) VP Joseph Francis Kelly Buys 2,500 Shares
Radius Health Inc (NASDAQ:RDUS) VP Joseph Francis Kelly purchased 2,500 shares of the company’s stock in a transaction on Friday, June 7th. The stock was acquired at an average price of $21.81 per share, for a total transaction of $54,525.00. Following the completion of the transaction, the vice president now owns 7,500 shares of the company’s stock, valued at approximately $163,575. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Joseph Francis Kelly also recently made the following trade(s):
- On Friday, May 10th, Joseph Francis Kelly bought 2,000 shares of Radius Health stock. The shares were acquired at an average cost of $21.43 per share, for a total transaction of $42,860.00.
NASDAQ RDUS traded down $0.02 during mid-day trading on Wednesday, reaching $21.20. The stock had a trading volume of 3,782 shares, compared to its average volume of 577,036. The company has a quick ratio of 5.04, a current ratio of 5.16 and a debt-to-equity ratio of 6.75. Radius Health Inc has a 1 year low of $12.81 and a 1 year high of $31.92. The firm has a market cap of $999.67 million, a P/E ratio of -4.37 and a beta of 0.99.
A number of research analysts have recently commented on RDUS shares. BidaskClub upgraded Radius Health from a “hold” rating to a “buy” rating in a report on Monday. Zacks Investment Research raised Radius Health from a “hold” rating to a “buy” rating and set a $24.00 target price on the stock in a research note on Monday, May 6th. Goldman Sachs Group raised Radius Health from a “neutral” rating to a “buy” rating and raised their price target for the stock from $26.00 to $38.00 in a research report on Wednesday, May 29th. Cowen restated a “hold” rating on shares of Radius Health in a research note on Wednesday, May 8th. Finally, Citigroup reiterated a “neutral” rating and set a $24.00 target price on shares of Radius Health in a research note on Thursday, May 30th. Five research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Radius Health has a consensus rating of “Buy” and a consensus price target of $33.14.
Several hedge funds and other institutional investors have recently bought and sold shares of RDUS. Bank of Montreal Can grew its position in shares of Radius Health by 231.3% in the fourth quarter. Bank of Montreal Can now owns 1,544 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 1,078 shares during the period. Great West Life Assurance Co. Can increased its stake in Radius Health by 95.3% during the 1st quarter. Great West Life Assurance Co. Can now owns 6,249 shares of the biopharmaceutical company’s stock worth $124,000 after buying an additional 3,049 shares during the period. SG Americas Securities LLC acquired a new position in Radius Health during the 1st quarter worth approximately $157,000. Ellington Management Group LLC acquired a new position in Radius Health during the 1st quarter worth approximately $203,000. Finally, Paloma Partners Management Co acquired a new position in shares of Radius Health in the 4th quarter valued at $218,000.
About Radius Health
Radius Health, Inc, a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator to treat breast cancer.
See Also: Dividend Achievers
Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.